Home
overview

SMi's Cell-Based Assays conference is now in its 3rd year - click here to view our 2010 event 

 

 


 
2009 Past Event Details:

Cell-based assays have developed into a rapid and cost-effective way of determining the challenges and issues in drug design and development.

Following on from the success of the inaugural event, the SMi Group will bring together the leading experts and professionals for their 2nd annual event on Cell-Based Assays, to discuss the most topical and relevant issues in this sector.

This year’s conference will provide delegates with the opportunity to gain a fresh insight into the various aspects of cell-based assays. With the aim of addressing topics from High Throughput and High Content screening to the use of 3D cell cultures, this event will cater for a breadth of people. With progressions and new developments in this exciting area of research, this event is a staple requirement for anyone looking to broaden their perspective and network with leading individuals in the field of cell-based assays. Particular focus with be placed on the developments in label free technologies and GPCR drug targetting.


 

Key benefits of attending:

  • GAIN an in depth understanding of the developments with label-free technologies
  • HEAR expert presentations on the topical issue of 3D cell cultures
  • DISCUSS novel technological advances
  • MEET the leading experts and professionals in the field of cell-based assays

 

Which companies are attending?

Registered companies include:

  • AstraZeneca
  • BioFocus
  • Boehringer Ingelheim
  • Galapagos
  • Genentech
  • GlaxoSmithKline
  • Imperial College Of London
  • MedImmune Cambridge
  • Merck Serono
  • Merck Sharp & Dohme
  • Novo Nordisk
  • Pfizer
  • Pfizer Global R&D
  • Roche Diagnostics
  • UCB Pharma
  • Vernalis
 

Last year's speakers and delegates included Directors, Managers, Heads, Group Leaders, Scientists and Researchers from:

  • Bayer Schering Pharma
  • Novartis Pharma
  • Genzyme
  • Genentech
  • Actelion
  • AstraZeneca
  • Merck Serono
  • Pfizer

This event is aimed at people working within the following fields:

  • Drug target discovery / validation
  • Drug discovery
  • ADMET
  • Preclinical development
  • Pharmacokinetics
  • Drug metabolism
  • Disease profiling
  • Toxicology
  • Clinical research
  • Screening
  • Medicinal chemistry
  • Lead optimisation
  • Structural biology
  • Molecular and cell biology
  • Proteomics
  • Bioanalytical development
  • Kinase and GPCR assays
  • Bioassay development/ optimisation
  • Functional genomics

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Darren  Cawkill

Darren Cawkill, Senior Principal Scientist , Pfizer

9:10 LABEL-FREE SCREENING FOR GPCR LIGANDS

Clay Scott

Clay Scott, Associate Director, Lead Generation , AstraZeneca Pharmaceuticals

  • How does it compare to traditional methods?
  • Where is it best utilized in the drug discovery process?
  • Do impedence-based and optical-based biosensors give similar results?
  • 9:50 USING HUMAN EMBRYONIC STEM CELLS FOR DRUG DISCOVERY

    Paul Andrews

    Paul Andrews, Senior Scientist, Drug Discovery Unit, University of Dundee

  • Human Embryonic Stem Cells (hESCs) now can be employed for drug discovery
  • High Content Screening ideally suited for hit identification and secondary assays
  • Screens for small molecules that influence stem cell fate have been performed successfully
  • Future hold great promise for more physiologically relevant cell models of disease
  • 10:30 Morning Coffee

    11:00 PRINCIPLES AND APPLICATIONS OF LABEL-FREE CELL BASED ASSAYS

    Sylvie Bailly

    Sylvie Bailly, Corning Epic® Applciation Scientist, Corning Life Sciences

  • Introduction to the Epic® system
  • Cell assays principle
  • Some applications: GPCR, cytotoxicity, ion channel
  • Compound library screening
  • 11:40 CASE STUDIES:

    James Brady

    James Brady, Director, Technical Applications , MaxCyte Inc

  • Replacing stable cell lines with transiently transfected cells
  • Advantages of large scale transfections by electroporation
  • Successful applications in cell based assays
  • 12:20 Networking Lunch

    13:30 THREE-DIMENSIONAL IMAGING AND THREE-DIMENSIONAL SPECIMENS

    Dr Ernst H. K. Stelzer

    Dr Ernst H. K. Stelzer, Scientific Group Leader, European Molecular Biology Laboratory

  • Light sheet based fluorescence microscopy
  • Three-dimensional cell biology
  • Novel approaches to physiologically relevant model-based life sciences
  • Drug and toxicity tests with three-dimensional cell-based assays
  • 14:10 EXPANDING THE USE OF PRIMARY CELL SYSTEMS IN HIT IDENTIFICATION AND COMPOUND PROFILING

    Steven Ludbrook

    Steven Ludbrook, Section Head, GlaxoSmithKline

  • Highly representative of the in vivo state: characteristics of specific drug targets behaving in their native form
  • Used together with animal in vivo models and human disease tissue systems to progress drug molecules to clinical trials.
  • Advances in sensitive screening technologies and enhanced diversity and availability of primary cell assay samples enable the use of primary cell assays at earlier stages in drug discovery programmes.
  • Examples of mechanistic and phenotypic assays in primary cell systems, together with an outlook for future directions
  • 14:50 Afternoon Tea

    15:20 CELL-BASED ASSAYS THAT DETECT MECHANISMS OF HUMAN HEPATOTOXICITY

    Katya  Tsaioun

    Katya Tsaioun, President, Apredica

  • Science and economics of drug-induced liver injury
  • Assays wih transformed or primary cells?
  • Single end point or multiparameter readout?
  • Validation data and case studies
  • 16:00 BETTER CELLS LEAD TO BETTER DATA : IMPROVING CELL LINE GENERATION

    Darren  Cawkill

    Darren Cawkill, Senior Principal Scientist , Pfizer

  • Importance of cell line development for enabling cell-based assays
  • Case study: fluorescence activated cell sorting (FACS) and automation (Cello) to generate high quality cell lines for difficult targets
  • Case study: Investment in thorough cell line characterisation is worthwhile
  • Could we replace recombinant cell lines with primary cells in our early cell-based screening?
  • Case study: Possibilities regarding assay development in primary cells
  • 16:40 OPTIMISATION OF ONCOLOGY CELL BASED SCREENING TO DRIVE EFFICIENCY

    Jon Orme

    Jon Orme, Associate Principal Scientist, AstraZeneca

  • Centralisation of cell based screening
  • Process quality - LIMS, Acoustic dispensing, automation
  • Efficiency improvements made in cell based screening - Multiplex assays, cmyc ELISA's
  • Future improvements
  • 17:20 Chairman’s Closing Remarks

    17:30 Drinks Reception Hosted by Cyntellect

    19:00 Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Nicholas Barnes

    Nicholas Barnes, Professor of Neuropharmacology, The University of Birmingham Medical School Medical School

    Anker Jon Hansen

    Anker Jon Hansen, Principal Scientist, Novo Nordisk

    9:10 HIGH CONTENT ANALYSIS IN EARLY DRUG DISCOVERY

    Philip Denner

    Philip Denner, Screening, High-Content Analysis, Bayer Schering Pharma

  • Image analysis tools
  • Mechanistic pathway analysis
  • Use of living cells in functional HCA
  • 9:50 LABEL-FREE DETECTION OF CELL ACTIVATION AND CELL ADHESION

    Anker Jon Hansen

    Anker Jon Hansen, Principal Scientist, Novo Nordisk

  • Human Embryonic Stem Cells (hESCs) now can be employed for drug discovery
  • High Content Screening ideally suited for hit identification and secondary assays
  • Screens for small molecules that influence stem cell fate have been performed successfully
  • Future hold great promise for more physiologically relevant cell models of disease
  • 10:30 Morning Coffee

    11:00 THE CELLKEY™ SYSTEM

    Johannes Pschorr

    Johannes Pschorr, European Application Scientist, MDS Analytical Technologies

  • Principles of Cellular Dielectric Spectroscopy and impedance-based measurements
  • Analysis of signal transduction pathways of receptors
  • Compound library screening and pharmacological profiling
  • Case study: demonstrating biorelevance of the CellKey™ assay technology
  • 11:40 MODELLING THE HUMAN IMMUNE RESPONSE

    John  Gordon

    John Gordon, Professor of Cellular Immunology, Medical Research Council Centre for Immune Regulation

  • The need for HUMAN immuno-profiling
  • Unfortunately mice can lie
  • Central players (the immune cell subsets and their procurement)
  • Reconstituting the human immune response ex vivo
  • Who benefits? (Answer = Patients & Industry)
  • 12:20 Networking Lunch

    13:50 SIGNALLING PATHWAY-SELECTIVE GPCR ACTIVATION

    Klaus Mohr

    Klaus Mohr, Pharmacology & Toxicology Section, University Of Bonn

  • Signalling-dependent cellular dynamic mass redistribution
  • Real-time measurement by an optical biosensor technique
  • Case study: Allosteric/orthosteric GPCR activators – fine-tuning efficacy and signalling
  • 14:30 MULTIDIMENSIONAL FLUORESCENCE IMAGING

    Paul French

    Paul French, Head of Photonics Group, Imperial College London

  • Fluorescence lifetime imaging
  • Spectrally-resolved and polarisation-resolved imaging
  • Label-free contrast of diseased tissue
  • Imaging local fluorophore environment
  • High speed FLIM and FRET
  • Multiplexed FRET
  • tomoFLIM and tomoFRET – applied to optical projection tomography and fluorescence molecular tomography
  • 15:10 Afternoon Tea

    15:40 TARGETING WNT SIGNALLING IN CANCER

    16:20 Chairman’s Closing Remarks

    16:30 Close of Conference

    +

    Workshops

    Cell Based Assays and High Content Analysis
    Workshop

    Cell Based Assays and High Content Analysis

    Crowne Plaza Hotel - St James
    17th November 2009
    London, United Kingdom

    Crowne Plaza Hotel - St James

    Buckingham Gate 45/51
    London SW1E 6AF
    United Kingdom

    Crowne Plaza Hotel - St James

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.